Printer Friendly

IMMUNOMEDICS REPORTS ON REPEAT USAGEOF COLORECTAL CANCER DETECTION AGENT

 TORONTO, June 9 /PRNewswire/ -- At the 40th annual meeting of the Society of Nuclear Medicine in Toronto, Immunomedics, Inc. (NASDAQ-NMS: IMMU), Morris Plains, N.J., announced that in 18 patients who received a second injection of ImmuRAID(TM)-CEA, its monoclonal antibody-based imaging agent for detection of colorectal cancer, none developed an immune response to the foreign protein, known as HAMA (human anti-mouse antibodies). ImmuRAID-CEA is currently under review for marketing approval by the U.S. Food and Drug Administration, as well as by regulatory agencies in Europe and Canada.
 According to Dr. Carl M. Pinsky, vice president, medical affairs at Immunomedics, "In broader clinical studies with ImmuRAID-CEA completed as part of our Product License Application (PLA) filing with the FDA, less than one percent of patients developed HAMA responses after a single injection. The results of this study are clinically significant, suggesting that ImmuRAID-CEA may be appropriate for multiple injections in detection of colorectal cancer." Dr. Pinsky added that although the initial development of HAMA is usually harmless to the patient, high levels of HAMA antibodies can render subsequent doses of monoclonal- antibody based products ineffective for imaging purposes. "For this reason, the observation that none of the patients who received a second dose developed HAMA appears to be particularly pertinent."
 ImmuRAID-CEA, consisting of an antibody fragment labeled with the radioisotope technetium-99m, attaches to the tumor marker CEA (carcinoembryonic antigen) and allows for detection via a standard nuclear medicine camera. In clinical trials, CEA containing tumors were imaged by ImmuRAID-CEA as early as two hours post-injection. In addition to colorectal cancer, ImmuRAID-CEA is currently in Phase II trials for the detection of breast and lung cancers.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases. In addition to ImmuRAID-CEA, the company currently has two therapeutics and five imaging products in clinical trials.
 -0- 6/9/93
 /CONTACT: Debra Wasser, director - corporate communications of Immunomedics, Inc., 201-605-1330, Ext. 113/
 (IMMU)


CO: Immunomedics, Inc. ST: New Jersey, Ontario IN: MTC SU:

SH-LR -- NY012 -- 0053 06/09/93 09:51 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1993
Words:385
Previous Article:SKYWEST AIRLINES REPORTS MAY TRAFFIC
Next Article:TERRA INDUSTRIES REPORTS MAY REVENUE UP 11 PERCENT
Topics:


Related Articles
IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS
IMMUNOMEDICS REPORTS BENEFITS OF COLORECTAL CANCER IMAGING AGENT
POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING
IMMUNOMEDICS' COLORECTAL CANCER DETECTION AGENT ACCLAIMED AT SURGICAL CONGRESS: FINDINGS SHOW ACCURACY OF OVER 90 PERCENT
IMMUNOMEDICS TO RESEARCH CANCER VACCINE UNDER FEDERAL GRANT
IMMUNOMEDICS ELECTS ALBERT D. ANGEL TO BOARD OF DIRECTORS
IMMUNOMEDICS REPORTS ON POTENTIAL DIAGNOSTIC FOR AIDS-RELATED PNEUMONIA
NEW CANCER DETECTION AGENT CLEARED BY FDA
Immunomedic Engages Lehman Brothers As Financial Advisor
Immunomedics Invents New Vaccine Technology For Cancer And Infectious Diseases.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters